277 related articles for article (PubMed ID: 21692616)
1. Pharmacogenomics of the triazole antifungal agent voriconazole.
Mikus G; Scholz IM; Weiss J
Pharmacogenomics; 2011 Jun; 12(6):861-72. PubMed ID: 21692616
[TBL] [Abstract][Full Text] [Related]
2. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole therapeutic drug monitoring: focus on safety.
Pasqualotto AC; Xavier MO; Andreolla HF; Linden R
Expert Opin Drug Saf; 2010 Jan; 9(1):125-37. PubMed ID: 20021293
[TBL] [Abstract][Full Text] [Related]
4. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.
Hassan A; Burhenne J; Riedel KD; Weiss J; Mikus G; Haefeli WE; Czock D
Ther Drug Monit; 2011 Feb; 33(1):86-93. PubMed ID: 21192313
[TBL] [Abstract][Full Text] [Related]
5. Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.
Moriyama B; Falade-Nwulia O; Leung J; Penzak SR; JJingo C; Huang X; Henning SA; Wilson WH; Walsh TJ
Mycoses; 2011 Nov; 54(6):e877-9. PubMed ID: 21615537
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.
Weiss J; Ten Hoevel MM; Burhenne J; Walter-Sack I; Hoffmann MM; Rengelshausen J; Haefeli WE; Mikus G
J Clin Pharmacol; 2009 Feb; 49(2):196-204. PubMed ID: 19033450
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic profile of voriconazole.
Theuretzbacher U; Ihle F; Derendorf H
Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
[TBL] [Abstract][Full Text] [Related]
8. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Trégouet DA; Amrein C; Boussaud V; Chevalier P; Lillo-Lelouet A; Le Beller C; Laurent-Puig P; Beaune PH; Billaud EM; Loriot MA
Eur J Clin Pharmacol; 2011 Mar; 67(3):253-60. PubMed ID: 21038076
[TBL] [Abstract][Full Text] [Related]
9. Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype.
Geist MJ; Egerer G; Burhenne J; Mikus G
Antimicrob Agents Chemother; 2006 Sep; 50(9):3227-8. PubMed ID: 16940139
[No Abstract] [Full Text] [Related]
10. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.
Andrews E; Damle BD; Fang A; Foster G; Crownover P; LaBadie R; Glue P
Br J Clin Pharmacol; 2008 Apr; 65(4):531-9. PubMed ID: 18294327
[TBL] [Abstract][Full Text] [Related]
12. Analysis of cytochrome P450 gene polymorphism in a lupus nephritis patient in whom tacrolimus blood concentration was markedly elevated after administration of azole antifungal agents.
Fujita Y; Araki T; Okada Y; Aomori T; Shimizu R; Tomizawa T; Hiromura K; Nojima Y; Nakamura T; Yamamoto K
J Clin Pharm Ther; 2013 Feb; 38(1):74-6. PubMed ID: 22971159
[TBL] [Abstract][Full Text] [Related]
13. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children.
Narita A; Muramatsu H; Sakaguchi H; Doisaki S; Tanaka M; Hama A; Shimada A; Takahashi Y; Yoshida N; Matsumoto K; Kato K; Kudo K; Furukawa-Hibi Y; Yamada K; Kojima S
J Pediatr Hematol Oncol; 2013 Jul; 35(5):e219-23. PubMed ID: 23588332
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole: a new triazole antifungal.
Sabo JA; Abdel-Rahman SM
Ann Pharmacother; 2000 Sep; 34(9):1032-43. PubMed ID: 10981251
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.
Ikeda Y; Umemura K; Kondo K; Sekiguchi K; Miyoshi S; Nakashima M
Clin Pharmacol Ther; 2004 Jun; 75(6):587-8. PubMed ID: 15179414
[No Abstract] [Full Text] [Related]
16. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.
Wang G; Lei HP; Li Z; Tan ZR; Guo D; Fan L; Chen Y; Hu DL; Wang D; Zhou HH
Eur J Clin Pharmacol; 2009 Mar; 65(3):281-5. PubMed ID: 18982321
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
Driscoll TA; Yu LC; Frangoul H; Krance RA; Nemecek E; Blumer J; Arrieta A; Graham ML; Bradfield SM; Baruch A; Liu P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5770-9. PubMed ID: 21968355
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring of voriconazole in children.
Chen J; Chan C; Colantonio D; Seto W
Ther Drug Monit; 2012 Feb; 34(1):77-84. PubMed ID: 22210097
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy.
Amsden JR; Gubbins PO
Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1135-1146. PubMed ID: 29022838
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and clinical use of voriconazole.
Thompson GR; Lewis JS
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):83-94. PubMed ID: 19947892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
